Construction of an acute myeloid leukemia prognostic model based on m6A-related efferocytosis-related genes

BackgroundOne of the most prevalent hematological system cancers is acute myeloid leukemia (AML). Efferocytosis-related genes (ERGs) and N6-methyladenosine (m6A) have an important significance in the progression of cancer, and the metastasis of tumors.MethodsThe AML-related data were collected from...

Full description

Bibliographic Details
Main Authors: Ying Wang, Ting Bin, Jing Tang, Xiao-Jun Xu, Chao Lin, Bo Lu, Tian-Tian Sun
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1268090/full
_version_ 1827661560836784128
author Ying Wang
Ting Bin
Jing Tang
Xiao-Jun Xu
Chao Lin
Bo Lu
Tian-Tian Sun
author_facet Ying Wang
Ting Bin
Jing Tang
Xiao-Jun Xu
Chao Lin
Bo Lu
Tian-Tian Sun
author_sort Ying Wang
collection DOAJ
description BackgroundOne of the most prevalent hematological system cancers is acute myeloid leukemia (AML). Efferocytosis-related genes (ERGs) and N6-methyladenosine (m6A) have an important significance in the progression of cancer, and the metastasis of tumors.MethodsThe AML-related data were collected from The Cancer Genome Atlas (TCGA; TCGA-AML) database and Gene Expression Omnibus (GEO; GSE9476, GSE71014, and GSE13159) database. The “limma” R package and Venn diagram were adopted to identify differentially expressed ERGs (DE-ERGs). The m6A related-DE-ERGs were obtained by Spearman analysis. Subsequently, univariate Cox and Least Absolute Shrinkage and Selection Operator (LASSO) were used to construct an m6A related-ERGs risk signature for AML patients. The possibility of immunotherapy for AML was explored. The pRRophetic package was adopted to calculate the IC50 of drugs for the treatment of AML. Finally, the expression of characterized genes was validated by quantitative reverse transcription-PCR (qRT-PCR).ResultsBased on m6A related-DE-ERGs, a prognostic model with four characteristic genes (UCP2, DOCK1, SLC14A1, and SLC25A1) was constructed. The risk score of model was significantly associated with the immune microenvironment of AML, with four immune cell types, 14 immune checkpoints, 20 HLA family genes and, immunophenoscore (IPS) all showing differences between the high- and low-risk groups. A total of 56 drugs were predicted to differ between the two groups, of which Erlotinib, Dasatinib, BI.2536, and bortezomib have been reported to be associated with AML treatment. The qRT-PCR results showed that the expression trends of DOCK1, SLC14A1 and SLC25A1 were consistent with the bioinformatics analysis.ConclusionIn summary, 4 m6A related- ERGs were identified and the corresponding prognostic model was constructed for AML patients. This prognostic model effectively stratified the risk of AML patients.
first_indexed 2024-03-10T00:13:01Z
format Article
id doaj.art-5894c25d906f4230b8be91cf5c1f1305
institution Directory Open Access Journal
issn 1664-3224
language English
last_indexed 2024-03-10T00:13:01Z
publishDate 2023-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj.art-5894c25d906f4230b8be91cf5c1f13052023-11-23T15:56:46ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-11-011410.3389/fimmu.2023.12680901268090Construction of an acute myeloid leukemia prognostic model based on m6A-related efferocytosis-related genesYing Wang0Ting Bin1Jing Tang2Xiao-Jun Xu3Chao Lin4Bo Lu5Tian-Tian Sun6Department of Haematology. The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, ChinaDepartment of Haematology. The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, ChinaDepartment of Haematology. The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, ChinaDepartment of Haematology. The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, ChinaPediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics. The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, ChinaDepartment of Haematology. The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, ChinaDepartment of Haematology. The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, ChinaBackgroundOne of the most prevalent hematological system cancers is acute myeloid leukemia (AML). Efferocytosis-related genes (ERGs) and N6-methyladenosine (m6A) have an important significance in the progression of cancer, and the metastasis of tumors.MethodsThe AML-related data were collected from The Cancer Genome Atlas (TCGA; TCGA-AML) database and Gene Expression Omnibus (GEO; GSE9476, GSE71014, and GSE13159) database. The “limma” R package and Venn diagram were adopted to identify differentially expressed ERGs (DE-ERGs). The m6A related-DE-ERGs were obtained by Spearman analysis. Subsequently, univariate Cox and Least Absolute Shrinkage and Selection Operator (LASSO) were used to construct an m6A related-ERGs risk signature for AML patients. The possibility of immunotherapy for AML was explored. The pRRophetic package was adopted to calculate the IC50 of drugs for the treatment of AML. Finally, the expression of characterized genes was validated by quantitative reverse transcription-PCR (qRT-PCR).ResultsBased on m6A related-DE-ERGs, a prognostic model with four characteristic genes (UCP2, DOCK1, SLC14A1, and SLC25A1) was constructed. The risk score of model was significantly associated with the immune microenvironment of AML, with four immune cell types, 14 immune checkpoints, 20 HLA family genes and, immunophenoscore (IPS) all showing differences between the high- and low-risk groups. A total of 56 drugs were predicted to differ between the two groups, of which Erlotinib, Dasatinib, BI.2536, and bortezomib have been reported to be associated with AML treatment. The qRT-PCR results showed that the expression trends of DOCK1, SLC14A1 and SLC25A1 were consistent with the bioinformatics analysis.ConclusionIn summary, 4 m6A related- ERGs were identified and the corresponding prognostic model was constructed for AML patients. This prognostic model effectively stratified the risk of AML patients.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1268090/fullacute myeloid leukemiaN6-methyladenosineefferocytosisprognostic risk modelbioinformaticsdrug prediction
spellingShingle Ying Wang
Ting Bin
Jing Tang
Xiao-Jun Xu
Chao Lin
Bo Lu
Tian-Tian Sun
Construction of an acute myeloid leukemia prognostic model based on m6A-related efferocytosis-related genes
Frontiers in Immunology
acute myeloid leukemia
N6-methyladenosine
efferocytosis
prognostic risk model
bioinformatics
drug prediction
title Construction of an acute myeloid leukemia prognostic model based on m6A-related efferocytosis-related genes
title_full Construction of an acute myeloid leukemia prognostic model based on m6A-related efferocytosis-related genes
title_fullStr Construction of an acute myeloid leukemia prognostic model based on m6A-related efferocytosis-related genes
title_full_unstemmed Construction of an acute myeloid leukemia prognostic model based on m6A-related efferocytosis-related genes
title_short Construction of an acute myeloid leukemia prognostic model based on m6A-related efferocytosis-related genes
title_sort construction of an acute myeloid leukemia prognostic model based on m6a related efferocytosis related genes
topic acute myeloid leukemia
N6-methyladenosine
efferocytosis
prognostic risk model
bioinformatics
drug prediction
url https://www.frontiersin.org/articles/10.3389/fimmu.2023.1268090/full
work_keys_str_mv AT yingwang constructionofanacutemyeloidleukemiaprognosticmodelbasedonm6arelatedefferocytosisrelatedgenes
AT tingbin constructionofanacutemyeloidleukemiaprognosticmodelbasedonm6arelatedefferocytosisrelatedgenes
AT jingtang constructionofanacutemyeloidleukemiaprognosticmodelbasedonm6arelatedefferocytosisrelatedgenes
AT xiaojunxu constructionofanacutemyeloidleukemiaprognosticmodelbasedonm6arelatedefferocytosisrelatedgenes
AT chaolin constructionofanacutemyeloidleukemiaprognosticmodelbasedonm6arelatedefferocytosisrelatedgenes
AT bolu constructionofanacutemyeloidleukemiaprognosticmodelbasedonm6arelatedefferocytosisrelatedgenes
AT tiantiansun constructionofanacutemyeloidleukemiaprognosticmodelbasedonm6arelatedefferocytosisrelatedgenes